ImmunityBio (NASDAQ: IBRX) director exercises options, sells 75,000 shares

Rhea-AI Filing Summary

ImmunityBio, Inc. director Christobel Selecky reported option exercises and share sales in January 2026. On January 16, 2026, she exercised 50,000 stock options with a $2.98 exercise price for common stock and then sold 50,000 shares at $5.00 per share, leaving her with no directly held common stock after the sale. On January 20, 2026, she exercised an additional 25,000 stock options at $2.98 and sold 25,000 shares at a weighted average price of $7.50 to $7.52, again ending with no directly held common shares.

The Form 4 shows that after these transactions, she continued to hold stock options, with 117,937 options remaining after the first exercise and 92,937 options after the second. All of the option shares had fully vested on June 12, 2023, and the options are scheduled to expire on June 14, 2032. The filing notes that the reported sales were made under a Rule 10b5-1 trading plan that she adopted on June 12, 2025, indicating the transactions were pre-arranged rather than opportunistic.

Insights

Equity compensation and insider-transactions analyst

Pre-planned option exercises and sales by an ImmunityBio director look like routine equity compensation activity.

The report shows Christobel Selecky, a director of ImmunityBio, Inc., exercising vested stock options at an exercise price of $2.98 and immediately selling the resulting common shares on January 16, 2026 and January 20, 2026. She exercised a total of 75,000 options and sold the same number of shares at prices of $5.00 and a weighted average between $7.50 and $7.52. After each set of sales she held no common shares directly, while retaining sizeable option positions.

The footnotes state that all of the option shares had fully vested on June 12, 2023 and that the sales were carried out under a Rule 10b5-1 trading plan adopted on June 12, 2025. Such plans are designed to structure sales in advance and reduce concerns about trading on nonpublic information. The options are shown with an expiration date of June 14, 2032, so these transactions represent partial monetization of a longer-dated award rather than a full exit from equity-linked exposure.

From an investor perspective, this looks like routine insider diversification and compensation realization, rather than a new signal about ImmunityBio’s operations or outlook. The overall impact on the company’s capital structure appears limited, and the pre-planned nature and prior vesting of the options reduce interpretive weight a sophisticated investor might place on the timing of the sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Selecky Christobel

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		M		50,000	A	$2.98	50,000	D
Common Stock	01/16/2026		S(1)		50,000	D	$5	0	D
Common Stock	01/20/2026		M		25,000	A	$2.98	25,000	D
Common Stock	01/20/2026		S(1)		25,000	D	$7.506(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.98	01/16/2026		M			50,000	(3)	06/14/2032	Common Stock	50,000	$0	117,937	D
Stock Option (right to buy)	$2.98	01/20/2026		M			25,000	(3)	06/14/2032	Common Stock	25,000	$0	92,937	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

2. Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.50 to $7.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Philip LoScalzo, as Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in this ImmunityBio (IBRX) Form 4 filing?

The Form 4 identifies Christobel Selecky as the reporting person. She is listed as a director of ImmunityBio, Inc. and is not marked as an officer or 10% owner in this filing.

What transactions did Christobel Selecky report in ImmunityBio (IBRX) stock?

She reported two option exercises and matching share sales. On January 16, 2026, she exercised 50,000 stock options at an exercise price of $2.98 and sold 50,000 common shares at $5.00 per share. On January 20, 2026, she exercised 25,000 options at $2.98 and sold 25,000 shares at a weighted average price in the $7.50–$7.52 range.

Were the ImmunityBio (IBRX) insider sales under a Rule 10b5-1 trading plan?

Yes. A footnote explains that the sales reported in this Form 4 were effected under a Rule 10b5-1 trading plan adopted by Christobel Selecky on June 12, 2025. Such plans pre-arrange trades to help insiders comply with securities laws.

How many ImmunityBio (IBRX) stock options does the director hold after these transactions?

The derivative table shows that after the January 16, 2026 option exercise, she held 117,937 stock options, and after the January 20, 2026 exercise, she held 92,937 stock options. These options carry an exercise price of $2.98 and an expiration date of June 14, 2032.

Did Christobel Selecky retain any ImmunityBio (IBRX) common shares after the reported sales?

No. In both sets of transactions, the Form 4 shows zero common shares beneficially owned directly after each sale, while she continued to hold vested stock options.

When did the ImmunityBio (IBRX) director’s stock options vest and when do they expire?

A footnote states that 100% of the shares subject to the option award vested on June 12, 2023, which was the date immediately preceding the 2023 annual meeting of stockholders. The derivative table lists an expiration date of June 14, 2032 for these options.